Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
intestinal microbiota capsules
- Development stage
- Unknown
- Lead developer
- First Affiliated Hospital of Ningbo University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Intestinal microbiota capsules are an investigational live biotherapeutic product (LBP) consisting of a concentrated consortium of commensal bacteria derived from healthy human donors. Developed and studied by the First Affiliated Hospital of Ningbo University, these capsules are used for fecal microbiota transplantation (FMT) in the neoadjuvant setting for locally advanced rectal cancer (LARC). The therapy is administered orally in conjunction with the PD-1 inhibitor sintilimab and standard long-course chemoradiotherapy. The primary objective of this microbial therapy is to modulate the patient's gut microbiome to enhance the efficacy of immune checkpoint inhibition and potentially reduce the gastrointestinal toxicity associated with pelvic radiation and chemotherapy. Each dose typically contains approximately 1 x 10^13 bacteria.
- Other names
- intestinal microbiota transplantationfecal microbiota transplantationFMTintestinal microbiota-First Affiliated Hospital of Ningbo University-rectal cancer (locally advanced)
Beyond the preview
Go deeper on intestinal microbiota capsules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on intestinal microbiota capsules.